Skyrizi (Risankizumab) demonstrated its non-inferiority to Stelara in achieving clinical remission at 24 weeks and its superiority in endoscopic remission at 48 weeks for patients with moderate to severe Crohn’s disease. This data was presented at the UEG Week.
- Skyrizi met its primary endpoints of clinical remission at week 24 and endoscopic remission at week 48 compared to ustekinumab (Stelara).
- The phase 3b open-label SEQUENCE study involved 520 patients with Crohn’s disease who had failed one or more anti-tumor necrosis factor therapies.
- Patients were assigned to either Skyrizi or Stelara for 48 weeks. The primary endpoints were clinical remission at week 24 and endoscopic remission at week 48.
- Skyrizi showed a clinical remission rate of 58.6% vs. 39.5% for Stelara at week 24 and an endoscopic remission rate of 31.8% vs. 16.2% at week 48.
- The study also highlighted Skyrizi’s superiority in all ranked secondary endpoints, including clinical remission at week 48 and steroid-free endoscopic remission at week 48.
- Adverse events were comparable between the two groups, but serious adverse events and events leading to drug discontinuation were higher with Stelara.
Laurent Peyrin-Biroulet, MD, PhD, from the University Hospital of Nancy in France, emphasized the potential of Skyrizi as an effective interleukin-23 inhibitor. He stated that the SEQUENCE study adds valuable knowledge for healthcare providers aiming for new treatment goals in Crohn’s disease.